Abstract
Dipeptidyl peptidase -4 inhibitors represent a novel way to augment the incretin system and one of the newest class of medications in the treatment of type 2 diabetes mellitus. Their mechanism of action is to decrease the inactivation of glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide, both of which are involved in maintaining euglycemia subsequent to carbohydrate intake. Currently investigated agents include sitagliptin, vildagliptin, saxagliptin, linagliptin, and alogliptin. Each agent has been shown to provide significant improvements in glycemic control compared to placebo. They are effective when added to other oral diabetes agents and in the cases of sitagliptin, vildagliptin, and alogliptin in addition to insulin. These agents may not provide as significant improvement in glucose concentrations as some other medications including metformin, thiazolidinediones, or glucagon-like peptide 1 agonists. The lack of head to head clinical data comparing the various dipeptidyl peptidase 4 inhibitors does not allow for specific recommendations if one agent is more effective or safer than another within the class. Their side effect profile suggests they are very well tolerated and have few drug interactions. For patients with mildly elevated glucose concentrations, they are therapeutic options in both drug-naïve patients as well as those not optimally controlled on other diabetes medications.
Keywords: Dipeptidyl Peptidase 4 Inhibitors, Incretin, Type 2 diabetes mellitus
Current Diabetes Reviews
Title:An Update in Incretin-Based Therapy: A Focus on Dipeptidyl Peptidase - 4 Inhibitors
Volume: 8 Issue: 3
Author(s): Brian K. Irons, Jessica M. Weis, Megan R. Stapleton and Krystal L. Edwards
Affiliation:
Keywords: Dipeptidyl Peptidase 4 Inhibitors, Incretin, Type 2 diabetes mellitus
Abstract: Dipeptidyl peptidase -4 inhibitors represent a novel way to augment the incretin system and one of the newest class of medications in the treatment of type 2 diabetes mellitus. Their mechanism of action is to decrease the inactivation of glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide, both of which are involved in maintaining euglycemia subsequent to carbohydrate intake. Currently investigated agents include sitagliptin, vildagliptin, saxagliptin, linagliptin, and alogliptin. Each agent has been shown to provide significant improvements in glycemic control compared to placebo. They are effective when added to other oral diabetes agents and in the cases of sitagliptin, vildagliptin, and alogliptin in addition to insulin. These agents may not provide as significant improvement in glucose concentrations as some other medications including metformin, thiazolidinediones, or glucagon-like peptide 1 agonists. The lack of head to head clinical data comparing the various dipeptidyl peptidase 4 inhibitors does not allow for specific recommendations if one agent is more effective or safer than another within the class. Their side effect profile suggests they are very well tolerated and have few drug interactions. For patients with mildly elevated glucose concentrations, they are therapeutic options in both drug-naïve patients as well as those not optimally controlled on other diabetes medications.
Export Options
About this article
Cite this article as:
K. Irons Brian, M. Weis Jessica, R. Stapleton Megan and L. Edwards Krystal, An Update in Incretin-Based Therapy: A Focus on Dipeptidyl Peptidase - 4 Inhibitors, Current Diabetes Reviews 2012; 8 (3) . https://dx.doi.org/10.2174/157339912800564007
DOI https://dx.doi.org/10.2174/157339912800564007 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
Call for Papers in Thematic Issues
Advancing Diabetic Wound Healing: Mechanisms and Interventions
In recent years, diabetic wounds have become a global health concern with the increase in the incidence of diabetes. Diabetic wounds are a kind of chronic and refractory ulcer. It is generally due to the microcirculatory disturbances and the reduced levels of endogenous growth factors. Delayed cutaneous wound healing is ...read more
Oxidative and inflammatory responses in the development of secondary diabetic complications
Diabetes, along with its associated secondary complications, represents a significant global health challenge, contributing significantly to morbidity and mortality. Unhealthy lifestyle habits, reduced physical activity, environmental pollutants, and stress are pivotal factors in the onset of diabetes, particularly type-2 diabetes. Poorly managed hyperglycemia can lead to various complications, including neuropathy, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aliskiren: A New Drug for an Old Problem
Cardiovascular & Hematological Agents in Medicinal Chemistry In Silico Validation for the Modulatory Effect of Tea Catechins on Erythrocyte Na<sup>+</sup>/K<sup>+</sup>-ATPase
The Natural Products Journal Cognitive Impairment and Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Pharmacological and Biological Activities of Xanthones
Anti-Infective Agents in Medicinal Chemistry The First Total Syntheses of the Diglycosides Virgaureoside A, of Solidago virgaurea L., and its Analogue iso-Virgaureoside A
Current Organic Synthesis Current Concepts in the Management of Diabetic Polyneuropathy
Current Diabetes Reviews Discovery Approaches for Novel Dyslipidemia Drugs
Current Drug Discovery Technologies Vitamin D and Cardiovascular Disease: A Novel Agent for Reducing Cardiovascular Risk?
Current Vascular Pharmacology Recent Advances in Liver X Receptor Biology and Chemistry
Current Topics in Medicinal Chemistry MicroRNA Dysregulation in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Challenges in Vascular Repair by Endothelial Progenitor Cells in Diabetic Patients
Cardiovascular & Hematological Disorders-Drug Targets Spontaneous (Autoimmune) Chronic Urticaria in Children: Current Evidences, Diagnostic Pitfalls and Therapeutic Management
Recent Patents on Inflammation & Allergy Drug Discovery Recent Advances in Obesity Pharmacotherapy
Current Clinical Pharmacology Management of Statin-Intolerant High-Risk Patients
Current Vascular Pharmacology Drugs in Newborn Resuscitation: The More We Learn the Least We Use
Current Medicinal Chemistry Review Metabolomics: A New Approach to Drug Delivery in Perinatology
Current Medicinal Chemistry Evolution of Exenatide as a Diabetes Therapeutic
Current Diabetes Reviews Evaluation of the Prevalence of Sleep Disorder Among Patients with Type 2 Diabetes Mellitus Referring to Ghaem Hospital from 2016 to 2017
Current Diabetes Reviews Prevalence of Diabetes Ketoacidosis Rises and Still No Strict Treatment Adherence
Current Diabetes Reviews Genetic Polymorphism of LDLR (rs688) is Associated with Primary Intracerebral Hemorrhage
Current Neurovascular Research